Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.

Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.

Key Topics Include:

  • Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
  • Describe how CMS will determine fair market prices for Medicare Part D drugs
  • Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.


Director, Client Engagement
Pricing, Market Access and Reimbursement

Mark McCoy has over 25 years of experience in US and global pharmaceutical marketing and specializes in market access communications. His extensive experience includes developing and communicating powerful value propositions for prelaunch and launch brands in a broad range of therapeutic categories.

Divisional Principal
Market Access

Earlene Biggs has over 20 years of experience delivering insights and strategies optimizing access and stakeholder engagement for pharmaceutical and biotech companies across the product lifecycle. In the past 5 years she has led her teams to successfully deliver 200+ research and analytics engagements with ICON clients.

Head of Business Intelligence
Commercial Solutions

Bruce Capobianco has supported business technology for over 20 years. He is a thought partner and trusted business advisor to clinical and commercial businesses by contributing to innovative and efficient study designs through robust evidence generation. Bruce is an evangelist in developing and driving adoption to AI to accelerate research.

VP, Scientific Affairs
Oncology Medical Strategy

Tanja Obradovic's experience includes 20+ years in clinical research as well as medical strategy leadership of oncology immunotherapy drug treatment value and reimbursement policy including packages for major private and public insurers and regulatory bodies such as CMS and NICE.

VP, PMAC Consulting
Patient Insight, Market Access and Commercial

Ki Park leads a team of principal SMEs with expertise in advanced analytics in the areas of payer, patient, promotional effectiveness, and commercial strategy. His 15 years at Symphony Health has focused on healthcare claims informatics specializing in payer and patient analytics.

Senior Principal
Global Health Economics and Outcomes Research

Nancy Risebrough is a Senior Principal within Global Health Economics and Outcomes Research at ICON. She has more than 20 years of experience working in decision analytic-modeling, health technology assessment (HTA), burden of illness studies, and reimbursement strategy and HTA submissions. Areas of therapeutic expertise include oncology, COPD, asthma, diabetes, and blood disorders.

Production Partner


ICON is a global provider of consulting, and outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We focus our innovation on the factors that are critical to our clients - reducing time to market, reducing cost and increasing quality.

Additional Content From ICON

Social Media Data: Opportunities and Insights for Clinical Research

Social Media Data: Opportunities and Insights for Clinical Research

Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.

Additional Content From HealthEconomics.Com

Related Content